Bevacizumab is a well-known and potent VEGF inhibitor and has been mostly used as an additional chemotherapeutic agent, especially, in solid tumors including malignant mesothelioma, non-small cell lung cancer, colorectal cancer, renal cancer, and breast cancer. The gene discussed is VEGFA; the disease is non-small cell lung carcinoma.